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Soluble fms-like tyrosine kinase receptor (sFlt-1) is a soluble form of extramembrane part of vascular endothelial growth factor
receptor-1 (VEGFR-1) that has antitumor effects. Bifidobacterium Infantis is a kind of non-pathogenic and anaerobic bacteria that
may have specific targeting property of hypoxic environment inside of solid tumors. The aim of this study was to construct
Bifidobacterium Infantis-mediated sFlt-1 gene transferring system and investigate its antitumor effect on Lewis lung cancer (LLC) in
mice. Our results demonstrated that the Bifidobacterium Infantis-mediated sFlt-1 gene transferring system was constructed
successfully and the system could express sFlt-1 at the levels of gene and protein. This system could not only significantly inhibit
growth of human umbilical vein endothelial cells induced by VEGF in vitro, but also inhibit the tumor growth and prolong survival
time of LLC C57BL/6 mice safely. These data suggest that Bifidobacterium Infantis-mediated sFlt-1 gene transferring system presents
a promising therapeutic approach for the treatment of cancer.
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Introduction
It has been widely accepted that the growth and progres-
sion of most solid cancers are angiogenesis-dependent.
1,2
Angiogenesis, defined as the production of new capillary
vessels and venules in a specific area,
3 is an essential
process for the primary tumor to grow and invade into the
adjacent normal structures.
4 It is a complex process
controlled by a balance of angiogenic and angiostatic
factors involved in multiple pathways that result in
endothelial cell proliferation, differentiation and organiza-
tion into a functional network of vascular channels.
5
Antiangiogenic therapy is one of the most promising
methods for the treatment of cancers.
6,7 This theory is
supported by enormous experiments and clinical trials.
8–12
For example, Avastin (bevacizumab), which is an anti-
angiogenesis antibody, was approved by Food and Drug
Administration in 2004 for the treatment of colorectal
cancer.
12 Antiangiogenic agents hold much promise to
serve as optimal therapeutic strategy of cancers.
13–15
Among the many reported angiogenic factors, vascular
endothelial growth factor (VEGF) is one of the most
powerful endothelial-cell-specific mitogens that have an
important role in the complicated process of angiogen-
esis.
4 The overexpression of VEGF has been described in
neoplastic cells and has also been associated with tumor
growth and progression.
16–18 Among the many reported
angiogenic factors, VEGF is commonly overexpressed in
various human tumors compared with normal tissues.
5
The fms-like tyrosine kinase receptor (Flt) is a transmem-
brane receptor of the tyrosine kinase family, which has
been identified as a receptor for VEGF. Previous studies
indicate that VEGF and its receptor Flt-1 have an
important role in tumor growth and metastasis, and are
associated with poor prognosis in clinical human
tumors.
16–18 First identified in 1993, the soluble Flt
(sFlt-1) was immediately found to exert powerful
antiangiogenesis function.
16–18 As the soluble form of
extracellular part of VEGF receptor-1 (VEGFR-1), sFlt-1
can compete with VEGFR-1 for VEGF and exert its
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18 It has been confirmed that sFlt-1 can suppress
both the growth and metastasis of solid tumor by many
investigations.
17,18
Most solid tumors develop regions of low oxygen
tension because of an imbalance in oxygen supply and
consumption.
4 Hypoxia in the tumor microenvironment
provides a great place for anaerobic microbes to survive.
Bifidobacterium Infantis is a kind of Bifidobacteria that is
non-pathogenic and anaerobic, and thus they can
selectively localize and proliferate in the hypoxic environ-
ment in several types of solid tumors after systemic
application.
19–22 The aim of this study was to construct
Bifidobacterium Infantis-mediated sFlt-1 gene transferring
system and investigate its antitumor effect on Lewis lung
cancer (LLC) in mice.
Materials and methods
Materials
A shuttle vector, PTRKH2-PsT plasmid containing
erythromycin
r gene, was kindly provided by Life Scientific
College of Fudan University (Shanghai, China). Strains
of Bifidobacterium Infantis 2001 were obtained from Key
Laboratory of West China School of Stomatology,
Sichuan University (Sichuan Province, China). Recombi-
nant Escherichia coli DH5a line containing pcDNA3.1/
sFlt-1 was constructed by our laboratory before.
9 LLC
cell line was provided by the State Key Laboratory of
Biomedicine, Sichuan University (Sichuan Province,
China). Female C57BL/6 mice (6–8 weeks age) weighing
between 16 and 18g were purchased from Experimental
Animal Center of Sichuan University (Sichuan Province,
China). Purification kit of plasmid, purification kit of
polymerase chain reaction (PCR) product, plasmid mini-
preparation kit, Wizard PCR Preps DNA Purification
System and gel extraction kit were purchased from Omega
(Bellingham, WA). PCR reaction test kit was purchased
from Tiangen (Beijing, China). DNA Marker III was
purchased from Tiangen or TransGen (Beijing, China).
T4 DNA ligase, BamHI, SalI and One Step RNA PCR
Kit were purchased from Takara (Dalian, China). Trizol
reagent was purchased from TransGen. 3-(4, 5-Di-
methylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT), lysozyme and trypsin were purchased from Sigma
(Santa Clara, CA). Dulbecco’s modified Eagle’s medium,
M199 medium and dimethylsulfoxide were purchased
from Gibco (Gaithersburg, MD). Mouse monoclonal
antibody for sFlt-1 was purchased from R&D (Minnea-
polis, MN). Mouse monoclonal antibody for CD31 and
LSAB kit were purchased from Dako (Copenhagen,
Denmark). Polyvinylidene difluoride membranes were
purchased from Millipore (Boston, MA). The enhanced
chemiluminescence detection kit and X-ray films were
purchased from Roche (Basel, Switzerland).
Amplification of sFlt-1 gene
Strains of recombinant E. coli DH5a line containing
pcDNA3.1/sFlt-1 were inoculated into 5ml LB liquid
medium (containing ampicillin 50mgml
 1) with shaking,
overnight at 371C. On the second day, genomic DNA was
prepared by phenol/chloroform method and used as
template DNA to perform PCR for the amplification of
sFlt-1 gene. Specific primers of sFlt-1 gene were designed
based on published sequences (GenBank: AF063657)
and synthesized by Invitrogen (Shanghai, China). The
upstream primer is 50-TGAGGATCCATGGAGAGCAA
GGT-30 and the downstream primer is 50-GTGGTC
GACTTTTTCATGGACCCT-30 (the underlined place
was endonuclease site of BamHI and SalI). The PCR
product was a 969bp for sFlt-1 fragment. The amplifica-
tion cycle was repeated 35 times with the condition of
denaturation at 941C for 30s, annealing at 551C for 30s
and extension at 721C for 2min. Amplified products were
purified with Wizard PCR Preps DNA Purification
System and separated with electrophoresis of 0.8%
agarose gel to confirm whether the amplified products
had the desired size.
Digestion of sFlt-1 gene and PTRKH2-PsT plasmid
The recombinant E. coli DH5a line containing PTRKH2-
PsT was resuscitated and amplified. PTRKH2-PsT
plasmid was extracted from recombinant E. coli DH5a
using plasmid mini-preparation kit. The sFlt-1 gene 1mg
and PTRKH2-PsT plasmid 1mg were added into 10ml
10  Buffer E reactions, separately. Then, the sFlt-1 gene
and plasmid were digested with dual restriction endo-
nucleases (1.5ml BamHIþ1.5ml SalI) at 371C for 4h.
Once the digestion was complete, the DNA fragments
were separated by electrophoresis with 0.8% agarose gel.
The desired bands of about 6.9 and 1kb were cut out
from the gel. The DNA fragments in the gel were
extracted and recovered with gel extraction kit.
Ligation of plasmid vector fragment and sFlt-1 gene
fragment
Recovered sFlt-1 gene fragment 9ml, recovered pTRKH2-
PsT plasmid vector fragment 3ml and T4 DNA ligase 1ml
were added into the microfuge tube. The reactions were
incubated at 161C overnight. Then, the ligation products
and recombinant pTRKH2-PsT/sFlt-1 plasmids were
separated by electrophoresis to confirm whether they
had the desired size.
Transformation of Bifidobacterium Infantis
Bifidobacterium Infantis 2001 was cultured in MRS solid
plate medium and washed completely using ice-cold pure
water and resuspended in 40ml ice-cold sucrose (0.5 M)
containing ammonium citrate (1mm). Recombinant
pTRKH2-PsT/sFlt-1 plasmid 5ml( 1 mg )w a sa d d e dt ot h e
bacterial suspensions, and then they were mixed and
transferred to electroporation cuvette. Electroporation was
carried out to transform recombinant pTRKH2-PsT/sFlt-1
plasmid into Bifidobacterium Infantis at 2.0kV for 10ms.
Culture of transformed Bifidobacterium Infantis
When electroporation was completed, 1ml MRS liquid
medium containing Ery 10mgml
 1, 0.05% cysteine
hydrochloride and 0.5 M sucrose were added into the
electroporation cuvette to resuspend bacteria. Then,
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EP tube and incubated into anaerobic environment at
371C. After 2.5h, bacteria suspensions were cultured on
MRS plate medium with Ery 10mgml
 1, 0.05% cysteine
hydrochloride and 0.5 M sucrose, and incubated into
anaerobic environment at 371C for 72h.
Screening of recombinant positive Bifidobacterium
Infantis
A single positively transformed bacterial colony of
Bifidobacterium Infantis was picked up and inoculated
into 5ml erythromycin
r MRS liquid medium into anaero-
bic environment at 371C for 24h.
Digestion of recombinant plasmid and PCR
identification
Bacteria suspensions were added into the lysozyme with a
final concentration of 30mgml
 1, and cultured at 371C
for 40min. The plasmid DNA was extracted by small
dose plasmid extraction kit and digested by BamHI (1ml)
and SalI( 1 ml) at 371C for 4h. Then, the digested
products were identified by 0.9% agarose gel electro-
phoresis. The correct recombinant plasmid DNA identi-
fied by electrophoresis was used as template and amplified
through PCR using upstream and downstream primers.
The amplification cycle was repeated 30 times with the
condition of denaturation at 941C for 30s, annealing at
581C for 30s and extension at 721C for 1min 15s. Then,
the amplified products were identified by 0.9% agarose
gel electrophoresis.
Sequencing of inserted gene segment of recombinant
plasmid
Sequencing of inserted gene segment in recombinant
plasmid extracted from positively transformed bacteria
was performed using the method of Sanger dideoxy-
nucleotide triphosphate chain termination.
Detection of expression of sFlt-1 gene of recombinant
positive Bifidobacterium Infantis
The total RNA of recombinant positive colonies was
extracted by Trizol reagent. Reverse transcription (RT)-
PCR products were synthesized using total RNA as
template (30 times amplification cycle with the condition
of denaturation at 941C for 30s, annealing at 551C for
30s and extension at 721C for 1min). The amplified
products were subsequently identified through 0.9%
agarose gel electrophoresis.
Detection of expression of sFlt-1 protein by western blot
analysis
The positive transformed Bifidobacteria Infantis 100ml
were inoculated into 20ml erythromycin
r MRS liquid
medium into anaerobic environment at 371C for 24h.
Then, the bacteria were harvested by centrifugation,
resuspended in lysis buffer (50mM Tris-HCl, 2mM
EDTA, 100mM NaCl, 0.5% Triton X-100, 1mgml
 1
lysozyme, pH 8.5) and sonicated. Protein concentration
was determined by the bicinchoninic acid method. The
30mg protein was subjected to 4–12% gradient sodium
dodecyl sulfate-polyacrylamide gel electrophoresis using a
Tris–glycine system, and then the gel was electroblotted
onto polyvinylidene difluoride membrane for 45min. The
membrane was then incubated with 5% non-fat dry milk
in phosphate-buffered saline for 1h to block nonspecific
binding sites, and then incubated with the appropriate
primary antibody concentration (1:200 dilution for sFlt-1)
for 2h at 371C in 5% non-fat dry milk. The membrane
was subsequently rinsed in phosphate-buffered saline, and
then incubated for 2h at 371C with goat anti-mouse
immunoglobulin G-horse radish peroxidase at 1:2000
dilution. After incubation, the membrane was rinsed and
visualized with chemiluminescence detection reagents.
Effect of recombinant positive Bifidobacterium Infantis
on HUVEC proliferation
The recombinant Bifidobacteria Infantis containing
pTRKH2-PsT/sFlt-1 and pTRKH2-PsT plasmids were
broken by ultrasound and dialyzed to form a final
solution, respectively. Human umbilical vein endothelial
cells (HUVECs) were first digested with 0.25% trypsin
and counted. They were then diluted and inoculated into
a 96-well plate at a concentration of 1 10
4 cells per well
and a volume of 0.2ml per well in 40 wells. After culture
in the M199 medium containing fetal bovine serum, the
40 wells were randomized into four groups (10 wells per
group): group 1 (VEGF group) added with 0.2ml liquid
medium containing VEGF (6ngml
 1); group 2 added
with final solution of recombinant Bifidobacterium
Infantis containing pTRKH2-PsT/sFlt-1 plasmid 0.2ml
and VEGF (6ngml
 1); group 3 added with final solution
of recombinant Bifidobacterium Infantis containing
pTRKH2-PsT plasmid 0.2ml and VEGF (6ngml
 1);
and group 4 (negative control group) added with 0.2ml
liquid medium. During incubation at 371C for 24h,
0.02ml MTT (5mgml
 1 final concentration) was added
to each well. The plate was then incubated at 371C for an
additional 4h to allow MTT to form formazan crystals by
reacting with metabolically active cells. The formazan
crystals were solubilized in 0.15ml dimethylsulfoxide per
well at 371C for 10min. The absorbance values of the
solution in each well were measured at 490nm using a
microplate reader. Cell viability (%)¼absorbance of the
treated group/absorbance of VEGF group 100%.
Cell culture
LLC cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum plus
ampicillin and streptomycin routinely, and incubated in
5% CO2 at 371C.
Design of animal experiments
All animal procedures were approved by the Animal Care
and Scientific Committee of Sichuan University. The
tumor tissues from LLC mice were triturated and
prepared into cell suspensions (dilution 1:5 with normal
saline). The cells harvested from xenografts were adjusted
to the concentration of 1 10
7/ml, and 0.2ml cell
suspensions were injected subcutaneously into the armpit
of right anterior superior limbs of female C57BL/6 mice.
23
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2–4mm), the mice were randomized into the following
three groups eight mice per group): a control group (group
a) injected with 0.4ml saline into mice through the caudal
vein; a recombinant Bifidobacterium Infantis containing
pTRKH2-PsT/sFlt-1 plasmid group (group b) injected
with 0.4ml suspension of Bifidobacterium Infantis contain-
ing pTRKH2-PsT/sFlt-1 plasmid (1 10
8/ml) into
mice through the caudal vein; a recombinant Bifidobacter-
ium Infantis containing pTRKH2-PsT plasmid group
(group c) injected with 0.4ml suspension of Bifidobacter-
ium Infantis containing pTRKH2-PsT plasmid (1 10
8/
ml) into mice through the caudal vein. The injection
repeated six times every 3 days. All treatments lasted for
21 days.
Identification of specific targeting and sFlt-1 expression
in tumor tissue
Another 18 LLC bearing mice were divided into three
groups and received same treatment above. After 21 days,
all the mice were killed. The tumor tissue and other tissues
were cut in a sterile way. Part of the tumor tissue and
other tissues were homogenized using saline into a
concentration of 10%, respectively. A measure of 100ml
of homogenate of all the tissues was cultured on MRS
plate medium with Ery 10mgml
 1, 0.05% cysteine
hydrochloride and 0.5 M sucrose, and incubated into
anaerobic environment at 371C for 72h. The 20mg
protein extracted from tumor tissue of each group was
subjected to 4–12% gradient sodium dodecyl sulfate-
polyacrylamide gel electrophoresis using a Tris–glycine
system and then the gel was electroblotted onto poly-
vinylidene difluoride membrane for 45min. The mem-
brane was then incubated with 5% non-fat dry milk in
phosphate-buffered saline for 1h to block nonspecific
binding sites, and then incubated with the appropriate
primary antibody concentration (1:200 dilution for sFlt-1)
for 2h at 371C in 5% non-fat dry milk. The membrane
was subsequently rinsed in phosphate-buffered saline, and
then incubated for 2h at 371C with goat anti-mouse
immunoglobulin G-horse radish peroxidase at 1:2000
dilution. After incubation, the membrane was rinsed and
visualized with chemiluminescence detection reagents.
Tumor growth
The length, width and weight of tumor were callipered
every 3 days for tumor growth, and tumor volume (TV)
was estimated using the formula: TV (mm
3)¼
(width
2 length)/2.
Observation of necrosis and signals of blood flow in
tumor by color Doppler ultrasound
At 21 days after the treatment, the living mice in all
groups underwent color Doppler ultrasound before being
killed. The size, shape of tumor, ultrasonic echo
from tumor inner to known liquefied tumor and necrotic
tissues were detected under the two-dimensional ultra-
sound by color Doppler (ACUSON 1228ST) with 5MHz
frequency.
Signals of blood flow in tumor were detected by color
Doppler flow imaging (CDFI) with color Doppler
(5MHz). Signals of blood flow in the tumor of CDFI
were classified into four grades based on the criteria of
Adler:
24 0, no blood flow signals detected within the
tumor; I, minimal blood flow (one or two dot-like or a
thin- and short-like blood flow signals detected within the
tumor); II, moderate blood flow (up to three dot-like
blood flow signals or one longer blood flow signals
detected within the tumor); and III, abundant blood flow
(more than five dot-like blood flow signals or two longer
blood flow signals detected within the tumor).
Inhibitive rate of the tumor
Inhibitive rate of the tumor was calculated using the
formula:
23,25–26 inhibitive rate of the tumor
(%)¼(1 average tumor weight in treated group/average
tumor weight in control) 100%.
Necrosis rate of the tumor
The necrosis rate of the tumor was calculated by the
principle of Cavalieri
27,28 and was assessed using patho-
logical slices way.
23 The necrosis rate of the tumor
was determined using the following formula: necrosis
rate of the tumor¼tumor necrotic area/whole tumor
area 100% (tumor necrotic area¼the largest diame-
ter the smallest diameter of the tumor necrotic area;
whole tumor area¼the largest diameter the smallest
diameter of the tumor area).
Immunohistochemical detection of CD31 and detection
of microvessel density
Tumor tissues were fixed immediately in 10% buffered
formalin phosphate and embedded in paraffin. Immuno-
histochemical staining was performed using the EnVision
method. Briefly, the dewaxed, rehydrated sections (5mm)
were treated with 0.3% hydrogen peroxide in methanol
for 15min to block endogenous peroxidase activity, and
then washed three times with Tris-HCl-buffered saline.
The sections were repaired in citric acid antigen repair
solution (pH 6.0) for 40min, followed by treatment with
primary antibody at 371C for one night (anti-CD31
diluted for 1:100). After being washed with Tris-HCl-
buffered saline, sections were then treated with EnVi-
sion
TM diluted for 1:100 at 371C for 45min and washed
with Tris-HCl-buffered saline. The sections were then
stained with 3,30-diaminobenzidine under the control of
light microscope and counterstained with hematoxylin.
Finally, the sections were dehydrated, fixed and analyzed
by light microscopy.
Microvessel density (MVD) was evaluated by immuno-
histochemical analysis with antibodies to the endothelial
marker CD31 and determined according to the method of
Weidner and colleagues.
29 Briefly, the immunostained
sections were initially screened at low magnification
( 40) to identify hot spots, which are the areas of
highest neovascularization. Any yellow brown-stained
endothelial cell or endothelial cell cluster that was clearly
separate from adjacent microvessels, tumor cells and
other connective tissue elements was considered a single,
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stained microvessels were counted in a single high-power
field ( 200), and the average vessel count in three hot
spots was considered the value of MVD. All counts were
performed by three investigators in a blinded manner.
Microvessel counts were compared between the observers
and discrepant results were reassessed. The consensus was
used as the final score for analysis.
23
Side effects, quality of life and survival
Another 30 mice were randomized into groups a, b and c
as mentioned above (10 mice per group) just to observe
survival rate. During the experiment period, side effects
such as appetite, weight loss, mental state, behavior
change, reaction to stimulation, ruffling of fur and so on
were observed. The survival time of every mouse was
recorded until all mice died.
Statistical analysis
TV, necrosis rate of the tumor and MVD were analyzed by
one-way analysis of variance, followed by the Student’s t-
test. Data of inhibitive rate of the tumor were analyzed by
w
2 test. Survival curves were constructed according to the
Kaplan–Meier method and statistical significance was
determined by the log-rank test. Grade of CDFI were
analyzed by Kruskal–Wallis test. All statistical analyses
were performed using the SPSS 16.0 software package. All
P-values were two-sided and Po0.05 was considered as
the significant level of difference.
Results
PCR amplification of sFlt-1 gene
The amplified products of sFlt-1 gene were detected by
0.8% agarose gel electrophoresis, and the results showed
that a specific segment with about 1kb (Figure 1a) was
obtained, which was almost the same size as that of sFlt-1
gene (969bp).
Identification of PCR amplified products,
enzyme-digested products and sequencing
The amplified products of pTRKH2-PsT/sFlt-1 plasmid
were also detected by 0.8% agarose gel electrophoresis,
and the data showed that a segment with about 1kb
(Figure 1b) was obtained, which was the same size as that
of sFlt-1 gene (969bp).
The digested products of pTRKH2-PsT/sFlt-1 plasmid
were also detected by agarose gel electrophoresis. The
results showed that the recombinant positive pTRKH2-
PsT/sFlt-1 plasmid is about 8kb, and there were two
segments of approximate 969bp and 6.9kb extracted
from the 8kb recombinant plasmid (Figure 1b), which
were equal to the size of sFlt-1 gene and pTRKH2-PsT
plasmid, respectively.
Sequencing results showed that the size and sequence of
nucleotide acid of inserted gene segment were completely
consistent with the size and sequence of nucleotide acid of
sFlt-1 gene (GeneBank: AF063657). The full length of
inserted gene fragment was 969bp. The sequence of two
ends of the inserted gene was also consistent with BamHI
and SalI sites. The sequencing identified that the foreign
gene, sFlt-1 gene, was correctly inserted into pTRKH2-
PsT plasmid and transferred into Bifidobacterium Infantis.
The data showed that targeting gene therapy system of
Bifidobacterium Infantis was successfully constructed.
RT-PCR testing of the expression of sFlt-1 gene in
recombinant Bifidobacterium Infantis
The results of RT-PCR electrophoresis of positive
transformed Bifidobacterium Infantis showed that there
was a specific segment about 1kb (Figure 1c). It proved
that the sFlt-1 gene could replicate in recombinant
Bifidobacterium Infantis.
Detection of expression of sFlt-1 protein by western blot
analysis
The expression of sFlt-1 protein from positive trans-
formed Bifidobacterium Infantis was assayed by western
blot analysis using a mouse monoclonal antibody for
sFlt-1. The results of western blot analysis showed that
12
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Figure 1 The results of electrophoresis and western blot. (a) Polymerase chain reaction (PCR) products of soluble fms-like tyrosine kinase
receptor (sFlt-1). Lane 1: sFlt-1; lane 2: DNA marker III. (b) Digestion of sFlt-1 and pTRKH2-PsT by restriction endonuclease and PCR products of
sFlt-1. Lane 1: 1kb DNA ladder; lane 2: recombinant plasmid pTRKH2-PsT/sFlt-1 digested by restriction endonuclease BamHI and SalI; lane 3:
recombinant plasmid pTRKH2-PsT/sFlt-1; lane 4: plasmid pTRKH2-PsT; lane 5: PCR products of sFlt-1 gene from recombinant plasmid pTRKH2-
PsT/sFlt-1; lane 6: PCR products of sFlt-1 gene from recombinant plasmid pcDNA3.1/sFlt-1; lane 7: DNA marker III (TransGen).
(c) Agarose gel electrophoresis of reverse transcription (RT)-PCR and PCR products from recombinant Bifidobacterium Infantis of pTRKH2-
PsT/sFlt-1. Lane 1: PCR products of sFlt-1 gene from recombinant plasmid pTRKH2-PsT/sFlt-1; lane 2: RT-PCR product of RNA purified from
Bifidobacterium Infantis with pTRKH2-PsT/sFlt-1; lane 3: DNA marker III (from TransGen). (d) Western blot analysis of the expression of sFlt-1
gene. A western blot band (36.26kDa) from Bifidobacterium Infantis transformed recombinant pTRKH2-PsT/sFlt-1 plasmid was shown (lane 1),
and no same band was shown from Bifidobacterium Infantis transformed recombinant pTRKH2-PsT (lane 2).
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infantis transformed recombinant pTRKH2-PsT/sFlt-1
plasmid (Figure 1d), which is consistent with the size
predicted by Expasy proteomics tools (36.26kDa).
Furthermore, there was no same band from Bifidobacter-
ium Infantis transformed recombinant pTRKH2-PsT
plasmid (Figure 1d). It proved that sFlt-1 could be
expressed at the level of protein in Bifidobacterium
Infantis transformed recombinant pTRKH2-PsT/sFlt-1
plasmid.
Effect of final solution of recombinant positive
Bifidobacterium Infantis on HUVECs
After being treated with the final solution of recombinant
positive Bifidobacterium Infantis for 24h, many HUVECs
were killed and only a few grew along the wall. Many cells
floated and quantities of cell debris were observed in the
medium. The cells left on the wall underwent significant
changes in morphology; the original shape was gone,
cytoplasm became rougher, the nucleus showed pycnosis
and the refraction decreased, demonstrating obvious
cellular damages. In contrast, HUVECs treated with
negative solution failed to demonstrate obvious morpho-
logical changes compared with the control. As shown in
Figure 2, the cell viability of groups 1 and 3 had no
significant difference (P40.05). However, the cell viabi-
lity of groups 2 and 4 were significantly lower than group
1( Po0.05). The results showed the VEGF could induce
the growth of HUVECs significantly and the final
solution of recombinant positive Bifidobacterium Infantis
could inhibit the growth of HUVECs induced by VEGF.
Specific targeting of recombinant Bifidobacterium
Infantis and sFlt-1 expression in tumor tissue
At 3 days after the incubation, we found that there were
many white colonies in the medium culturing tumor
tissue, and there was no colony growing in the medium
culturing other tissues like the heart, liver, lung, kidney
and spleen (Figure 3). These results proved that both
the recombinant Bifidobacterium Infantis containing
pTRKH2-PsT/sFlt-1 plasmid and pTRKH2-PsT plasmid
had good targeting property to tumor tissue. Hence, we
think that the Bifidobacterium Infantis had specifically
targeted to the tumor tissue.
The result of western blot (Figure 4) showed that a
band about 36.26kDa from Bifidobacterium Infantis
transformed recombinant pTRKH2-PsT/sFlt-1 plasmid
was shown, and no same band was shown from
Bifidobacterium Infantis transformed recombinant
pTRKH2-PsT or saline control group.
TV, tumor weight and inhibitive rate of the tumor
The treatment began on the seventh day after the mice
were injected with tumor cells. We recorded the volume
and weight of tumors and the following acceleration curve
was obtained (see Figure 5a). As shown in Figure 5a, the
TV of groups b and c were considerably smaller than that
of group a (Po0.05), and the TV in group b was much
lower than that in group c (Po0.05). The data of tumor
weight showed that the tumor weight of groups b and c
reduced significantly than that of group a (Po0.05), and
especially in group b (Po0.05) (Figure 5b). In addition,
inhibitive rate of the tumor in groups b and c showed an
appreciable increase compared with group a (Po0.05),
and more in group b (Po0.05) (Figure 5c). All the above
findings showed that the Bifidobacterium Infantis contain-
ing pTRKH2-PsT/sFlt-1 plasmid or pTRKH2-PsT plas-
mid both could inhibit the growth of tumor, and the
Bifidobacterium Infantis containing pTRKH2-PsT/sFlt-1
plasmid had more significant effect.
Tumor necrosis rate
The necrosis areas of tumor represented low or no echo
by color Doppler ultrasound. As shown in Figure 6, there
were massive necrotic areas in tumors of group b, and the
necrosis rate is (58.88±6.24)%, whereas there were just
small necrotic areas in groups a and c, and the necrosis
rate were (17.62±4.90)% and (22.75±5.73)%, respec-
tively. The necrosis rate of group b was significantly
bigger than that of groups a and c (Po0.05).
Signal of blood flow in tumor
As shown in Figure 7, CDFI showed that signals of blood
flow in tumor were the worst in group b and the best in
the control group. The signals of blood flow were mainly
levels 0–I (5/8) in the group b, whereas 100% at level II or
level III (8/8) in the control group. The signals were
intermediate in group c.
MVD
MVD was determined by counting the number of
microvessels per high-power field in the section with an
antibody reactive to CD31 (Figure 8a). The results
showed that MVD of group b was (12.9±3.90)/vision
( 200), whereas that of groups a and c were
(33.4±3.66)/vision ( 200) and (30.0±4.21)/vision
( 200), respectively (Figure 8b). The MVD in group b
is significantly lower than that in groups a and c
(Po0.05), whereas there was no statistical significance
between groups a and c (P40.05).
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All the mice in each group began to represent slight
syndromes such as bad appetite, stunt response, little
activity, colorless of fur on the 12th day after the
treatment and the syndromes became increasingly evident
in a time-dependent manner. However, there were no
significant differences between each group in mental
status, appetite, weight and so on.
The mice of group a began to die on the 29th day after
the treatment, and all the mice of group a died on the 41st
day after the treatment. The mice died from tumor
deterioration, excluding improper experimental manipu-
lation by mice anatomy. However, there were still 70%
and 20% of mice in groups b and c that were alive,
respectively (Figure 9). Compared with groups a and c,
the survival in group b was significantly prolonged
(Po0.05), whereas no statistical significance was found
between groups a and c (P40.05).
Discussion
Tumor angiogenesis, first reported by Aligie in 1945,
30 is
now believed to be one of the most crucial steps in tumor
growth and development of metastasis.
5 The tumor cells
must gain access to the vasculature in the primary tumor,
survive the circulation, arrest in the microvasculature,
grow in the target organ and induce angiogenesis.
Angiogenesis can also help in cancer metastasis in several
ways. The production of new vessels increase tumor
nutrition and oxygen supplement, allowing tumor cells to
Saline pTRKH2-PsT pTRKH2-PsT/sFlt-1
36.26 kDa
Figure 4 Western blot analysis of the expression of sFlt-1 gene in
tumor tissue. Saline: saline control group; pTRKH2-PsT: recombi-
nant Bifidobacterium Infantis containing pTRKH2-PsT plasmid
group; pTRKH2-PsT/sFlt-1: recombinant Bifidobacterium Infantis
containing pTRKH2-PsT/sFlt-1 plasmid group. The western blot
showed that a band of about 36.26kDa from Bifidobacterium Infantis
transformed recombinant pTRKH2-PsT/sFlt-1 plasmid was shown,
and no same band was shown from Bifidobacterium infantis
transformed recombinant pTRKH2-PsT or saline control group.
Tumor
Kidney Liver Spleen Kidney Liver Spleen
Kidney Liver Spleen
Heart
Saline pTRKH2-PsT
pTRKH2-PsT/sFlt-1
Lung
Tumor Heart Lung
Tumor Heart Lung
Figure 3 Analysis of targeting property of Bifidobacterium Infantis. Saline: saline control group; pTRKH2-PsT: recombinant Bifidobacterium
Infantis containing pTRKH2-PsT plasmid group; pTRKH2-PsT/sFlt-1: recombinant Bifidobacterium Infantis containing pTRKH2-PsT/sFlt-1
plasmid group.
Bifidobacterium deliver sFlt-1 for cancer gene therapy
H Zhu et al
890
Cancer Gene Therapygrow and providing a route of entry to the systemic
circulation. It is now clear that those tumors rarely spread
in the pre-vascular phase of the disease. Metastasis may
be enhanced by the fragmented basement membranes of
the new capillaries.
3 It is reported that angiogenesis is
essential for the growth of solid cancers beyond 2mm,
which is the limit of nutrient diffusion.
4,10,31 Angiogenesis
is also suggested as a prognostic factor in various solid
tumors, such as breast cancer, prostate cancer, gastric and
non-small-cell lung cancers.
1 The antiangiogenesis ther-
apy of cancer was developed rapidly as this theory was
presented as a antitumor method by Folkman in 1971.
1
Now there are many methods to treat cancer with the
mechanism of antiangiogenesis, and they become an
irreplaceable way to cure cancer.
9,13,32,33
VEGF is one of the most important stimulating factors
for revascularization of tumor tissue,
18 and it exerts the
function through the VEGFR. The sFlt-1 is a soluble
form of Flt-1, which is the extramembrane part of
VEGFR-1; it has the same high affinity for VEGF, but
could not conduct information for the lack of transmem-
brane and intramembrane parts.
16,17 In this regard,
several studies have reported the application of sFlt-1
gene therapy to inhibit angiogenesis to inhibit tumor
growth.
34 However, there are some reports that the
normal combination of VEGF and VEGFR can stimulate
ischemic tissue revascularization and inhibition of angio-
genic and inflammatory disorders. Hence, the usage of
sFlt-1 may bring in some side effects on normal ischemic
tissue and angiogenic and inflammatory disorders.
35–38
Therefore, there are some reports which suggest that
intravenous delivery of the sFlt-1 gene via replication-
deficient, infectivity-enhanced recombinant adenoviral
vectors will result in the overexpression of sFlt-1 in the
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39 Therefore,
tumor-specific targeting of the vectors and tumor-specific
expression strategies should be used to ensure a clinically
useful antiangiogenesis gene therapy.
In recent years, the lack of specific transfer system is
one of the main blockages in gene therapy of cancer.
40
Many vectors such as virus or liposome always could not
reach the interior of tumor; moreover, they can cause
many serious side effects, such as the pathogenic effects of
virus, the induction of tumor and so on.
41 However,
Bifidobacterium Infantis is recently confirmed to be one of
the most perfect vectors that can reach the inside of tumor
specifically and cause nearly no side effects on the body.
20
In fact, Bifidobacterium Infantis is a kind of non-
pathogenic Gram-positive anaerobes that live in the large
intestine and lower part of small intestine of human and
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Figure 6 Effect of Bifidobacterium Infantis-mediated pTRKH2-PsT/sFlt-1 delivery system on tumor necrosis. (a) Ultrasound images of tumor
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Figure 7 Observation of blood flow in tumors by color Doppler flow imaging (CDFI). (a) Blood flow image of tumor and (b) classification of blood
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Cancer Gene Therapyother mammals. They keep a coordinate commensalisms
relationship between our body and act as a protective
function of our body. It has been demonstrated by
researches that Bifidobacterium Infantis has a lot of
physiological functions, such as inhibiting pathogenic
bacteria, stimulating immune function, activating macro-
phage, enhancing the anti-infectious and antitumor
function of the body.
42 It has already been widely used
in food industry areas. As it is well established, the center
of the solid tumor is hypoxic because of rapid prolifera-
tion,
10 which lead to the specific targeting function
of Bifidobacterium Infantis. Yazawa et al.
43 injected
non-pathological strains of Bifidobacterium 105-A and
108-A into mice bearing lung cancer. After 168h, both
strains of bacteria were observed to have targeted and
colonized in the tumors, whereas no bacteria were found
in the liver, spleen, kidney, normal lung tissues or other
normal tissues.
43 When the anaerobic bacteria were used
as the gene transfer vector, it could specifically proliferate
and directly express foreign gene products in tumor
tissues. There is no need to transform cancer cells, which
highly improves the gene expression.
20,42 For aspects of
the specific targeting function and safety, we consider
Bifidobacterium Infantis to be the tumor-specific vector of
sFlt-1 gene to exert its antitumor effects.
In this study, we constructed the pTRKH2-PsT/sFlt-1
plasmid by a series of endogenous nucleases and ligase;
ultimately, the Bifidobacterium Infantis-mediated sFlt-1
gene transferring system was constructed by electropora-
tion. All the products were identified by electrophoresis or
western blot. We chose the positive colony after culture,
and the plasmid was cleaved by endogenous enzymes
and then identified through electrophoresis. The two
fragments on the electrophoresis gel were about 969bp
and 6.9kb, which corresponded to the size of sFlt-1 gene
and pTRKH2-PsT plasmid. In addition, the sequencing
results showed that it is consistent with sFlt-1 sequence in
GenBank. The results demonstrated that the pTRKH2-
PsT/sFlt-1 plasmid was successfully transferred to the
Bifidobacterium Infantis. The results of RT-PCR electro-
phoresis and western blot demonstrated that the sFlt-1 gene
was integrated into the genome of Bifidobacterium Infantis
and it could be expressed at the levels of gene and protein.
In our in vitro experiment, the growth of HUVECs
added with VEGF and final solution extracted from
recombinant positive Bifidobacterium Infantis were
inhibited significantly. Many HUVECs were killed and
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Cancer Gene Therapyonly a few grew along the wall. Many cells floated and
quantities of cell debris were observed in the medium. The
cells left on the wall underwent significant changes in
morphology; the original shape was gone, cytoplasm
became rougher, the nucleus showed pycnosis and the
refraction decreased. The effectiveness of our in vitro
experiment advocates a basis for our further study in vivo.
After our study on tumor bearing mice, our results
showed that both the recombinant Bifidobacterium
Infantis containing pTRKH2-PsT/sFlt-1and pTRKH2-
PsT plasmids had good targeting property to tumor
tissue. The sFlt-1 protein can be expressed in tumor tissue
in recombinant positive group. The tumor growth of the
recombinant Bifidobacterium Infantis containing
pTRKH2-PsT/sFlt-1 plasmid group was inhibited sig-
nificantly (Po0.05) and the survival was prolonged
significantly (Po0.05). All these results demonstrated a
very evident inhibitive effect of tumor of the recombinant
Bifidobacterium Infantis containing pTRKH2-PsT/sFlt-1
plasmid. Besides, as shown in the Result section, there
were some inhibition effects of tumor by Bifidobacterium
Infantis itself comparing group c with group a. The
mechanism is still not certain and it may be possible that
the Bifidobacterium Infantis can stimulate the inflamma-
tory response, induce the accumulation of immune cell
and promote the secreting of antitumor factors by
macrophage. It is also reported that the structure of cell
wall of Bifidobacterium Infantis had antitumor effects.
20
The local proliferation of Bifidobacterium Infantis com-
peting the nutrition with tumor cells may contribute to its
antitumor effects, too. However, the expression of sFlt-1
may have a more significant role comparing group b with
group c.
The results above showed a significant inhibition effect
of tumor growth. Then, we know it is correlated with
antiangiogenesis. Hence, we detected the tumor necrosis
rate and blood flow signals by color Doppler ultrasound
and measured the MVD through CD31 immunohisto-
chemistry to evaluate whether it is correlated with
antiangiogenesis. Our results showed that there were
massive necrotic areas in tumors of the recombinant
Bifidobacterium Infantis containing pTRKH2-PsT/sFlt-1
plasmid group and only a few dot-like blood flow signals
near the edge of tumors. However, there were just small
necrotic areas and abundant blood flow signals in tumors
of the saline control group (group a) and the recombinant
Bifidobacterium Infantis containing pTRKH2-PsT plas-
mid group (group c). Compared with groups a and c, the
tumor necrosis rate was significantly increased and the
blood flow signals and MVD were significantly decreased
in the recombinant Bifidobacterium Infantis containing
pTRKH2-PsT/sFlt-1 plasmid group. These results
demonstrated that the significant antitumor effects of
the recombinant Bifidobacterium Infantis containing
pTRKH2-PsT/sFlt-1 plasmid group were correlated with
the antiangiogenesis mechanism. The antiangiogenesis
mechanism of sFlt-1 is still not for sure. It may inhibit
angiogenesis through competing with VEGFR-1; also, it
can combine to VEGFR to form heterodimer to interfere
with the combination between VEGF and VEGFR.
7,44
As we mentioned before, the Bifidobacteria Infantis are
the normal bacteria living in the body of human and other
mammals and they keep a coordinate commensalism
relationship between our bodies. In fact, the Bifidobacter-
ium Infantis is widely used in the food industry areas.
Besides, it has been proved in animal experiments that
Bifidobacterium has no obvious influence on body weight,
peripheral leukocytes, temperature or survival time of
mice, hamsters, guinea pigs or rabbits. Moreover,
anaerobic bacteria are highly vulnerable to antibiotics
and very low doses of antibiotics are enough to kill them.
Even in the case of overgrowth, the bacteria can be easily
controlled by antibiotics, which further ensures its
safety.
20 In addition, Yazawa et al.
42,43 had proved the
high specific targeting property of Bifidobacterium to
tumor tissue. Our previous experiment also showed that
intravenous delivery of Bifidobacterium Infantis was
safe.
20 In this experiment, there were also no obvious
side effects on tumor bearing mice after intravenous
delivery of Bifidobacterium Infantis-mediated sFlt-1 gene
transferring system. Hence, we consider this system is safe
enough.
Conclusions
This study suggested that Bifidobacterium Infantis-
mediated sFlt-1 gene transferring system was successfully
constructed and could express sFlt-1 at the levels of gene
and protein. This system could significantly inhibit
growth of HUVECs induced by VEGF in vitro. More-
over, it could inhibit the tumor growth and prolong
survival time of LLC C57BL/6 mice safely. This may be a
promising therapeutic strategy for cancer patients.
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